Company Profile
Adial Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- ADIL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.80 USD (+18.52%)
Close
Last updated: August 6, 2026
5.06M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ADIL closed up 18.5% at $4.80. No new same-company headline was identified in the current news window.
Company overview
Business overview
Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.
Geographic Base and Sector Classification
Adial is headquartered in the United States and listed on NASDAQ, with a small-cap specialty-biopharma profile. It sits in addiction medicine rather than mainstream oncology or immunology.
Business Model Characteristics
The business depends on clinical progress, regulatory strategy, and the ability to show that its candidate can create a meaningful treatment option in addiction care. Investors usually watch proof-of-concept data, safety, and commercialization potential.
Position Within the Biotechnology Landscape
Adial occupies a niche addiction-medicine position within biotech. The stock is catalyst-sensitive because the company is still trying to prove a focused therapeutic thesis in a difficult indication.
Future catalysts
Adial’s catalyst is AD04 and the alcohol-use-disorder program, where any clinical or regulatory update can keep the story alive. The company still needs a stronger human signal.
Recent news
- 01
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
Source: Adial Pharmaceuticals
- 02
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Source: Adial Pharmaceuticals
- 03
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
Source: Adial Pharmaceuticals
- 04
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
Source: Adial Pharmaceuticals
- 05
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
Source: Adial Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Adial Pharmaceuticals (ADIL)?
Adial Pharmaceuticals (ADIL) most recently closed at 4.80 USD, a +18.52% move versus the previous session.
What is the market cap of Adial Pharmaceuticals (ADIL)?
Adial Pharmaceuticals currently has a market capitalization of 5.06M USD on BioPharmSignal.
What does Adial Pharmaceuticals do?
Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.
On which exchange is ADIL stock listed?
Adial Pharmaceuticals (ADIL) is associated with NASDAQ, United States, Biopharma.
What is Adial?
Adial’s catalyst is AD04 and the alcohol-use-disorder program, where any clinical or regulatory update can keep the story alive.
Which conditions is Adial Pharmaceuticals targeting with Adial?
Adial’s catalyst is AD04 and the alcohol-use-disorder program, where any clinical or regulatory update can keep the story alive.
How does Adial Pharmaceuticals describe recent progress with Adial?
Adial’s catalyst is AD04 and the alcohol-use-disorder program, where any clinical or regulatory update can keep the story alive.
What is Pharmaceuticals?
Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology.